As the American Association for Cancer Research (AACR) Annual Meeting approaches in April 2026, oncology experts from leading institutions are preparing to unveil transformative research that could reshape cancer care. This premier gathering brings together scientists, clinicians, and innovators to share breakthroughs spanning immunotherapy, precision medicine, and cutting-edge technologies.
Researchers from The University of Texas MD Anderson Cancer Center are set to present a diverse array of studies highlighting advancements in cancer treatment, and biology. Among the featured presentations, Dr. Caroline Chung, M.D., will lead discussions on practical applications of artificial intelligence in oncology during a session titled “AI in cancer care: Practical applications transforming oncology” on Friday, April 17, from 3:00 to 4:30 p.m. Pacific Time in Room 29 of the Upper Level Convention Center.
On Saturday, April 18, MD Anderson experts will deliver additional key presentations. Dr. Krina Patel, M.D., will discuss CAR T cell therapy in myeloma, focusing on durability, design, and the path to a functional cure, from 8:20 to 8:40 a.m. In Room 6 CF. Later that morning, Dr. Dihua Yu, M.D., Ph.D., will explore strategies to disrupt the pre-metastatic niche in a talk titled “Disrupting the ‘soil’: Exploring and targeting the pre-metastatic niche,” scheduled for 8:31 to 8:51 a.m. In Ballroom 20 AB.
Further contributions include work by Dr. Moran Amit, M.D., Ph.D., who will chair a session on mapping neural-immune circuits using spatial multi-omics in the tumor microenvironment from 10:00 to 11:30 a.m. In Ballroom 6 CF, followed by a presentation on translating spatial multiomics into clinical action at 11:03 to 11:16 a.m. In the same location.
In related developments, MD Anderson researchers are showcasing how mRNA vaccines—originally developed for COVID-19—may enhance the effectiveness of immune checkpoint inhibitors in cancer patients. Findings indicate that individuals who received mRNA vaccines within 100 days of starting checkpoint inhibitor therapy demonstrated doubled survival rates after three years, suggesting a promising avenue for combinatorial immunotherapy.
Additional research highlights include the use of spatial multi-omics to map metabolic heterogeneity in gliomas of varying grades, uncovering mechanisms behind treatment resistance and tumor proliferation. Scientists have also developed a large language model designed to integrate single-cell and spatial proteomics data, improving protein signal detection and cell type identification through an agentic framework that harmonizes complex datasets.
Clinical trial updates presented at the meeting include preliminary data from six pivotal studies. One notable trial examines zanidatamab, a bispecific antibody targeting HER2-positive early-stage breast cancer, which binds to two distinct epitopes on the HER2 receptor to enhance antitumor activity even as potentially reducing chemotherapy-related toxicities. Another focuses on perioperative nivolumab in resectable non-small cell lung cancer, integrating genomic data, pathologic complete response, and circulating tumor DNA dynamics to refine treatment personalization.
The AACR Annual Meeting serves as a critical platform for advancing cancer science, with MD Anderson’s contributions reflecting a broad commitment to innovation across immunotherapy, computational biology, and precision oncology. As these findings are shared, they hold the potential to influence future treatment strategies and improve outcomes for patients worldwide.